Henoch-Schönlein purpura in a 6-year-old boy after initial COVID-19 vaccination.

Autor:	de Souza Campos Fernandes RC; Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil.; Universidade Estadual do Norte Fluminense, Avenida Alberto Lamego 2000, Campos dos Goytacazes, Rio de Janeiro, CEP 28013-602, Brazil., Nunes DV; Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil., de Almeida NF; Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil., da Cruz Assad Monteiro N; Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil., Pimenta LAM; Faculdade de Medicina de Campos, Avenida Alberto Torres 217, Campos dos Goytacazes, Rio de Janeiro, CEP 28035-581, Brazil., Medina-Acosta E; Universidade Estadual do Norte Fluminense, Avenida Alberto Lamego 2000, Campos dos Goytacazes, Rio de Janeiro, CEP 28013-602, Brazil.
Jazyk:	angličtina
Zdroj:	Vaccine: X [Vaccine X] 2023 Aug; Vol. 14, pp. 100333. Date of Electronic Publication: 2023 Jun 20.
DOI:	10.1016/j.jvacx.2023.100333
Abstrakt:	The COVID-19 pandemic has significantly impacted global health, and the widespread immunization of adults against SARS-CoV-2 has played a pivotal role in altering the course of the disease. While COVID-19 vaccine adverse events are generally uncommon and mild, the recent vaccination of the pediatric population has emphasized the need for vigilance and reporting of potential side effects. In this case report, we present a 6-year-old boy who developed Henoch-Schönlein purpura following the administration of the first dose of Pfizer-BioNTech BNT16B2b2 mRNA COVID-19 vaccine, making it the earliest reported case of such an adverse event. Our report highlights the importance of continued monitoring and reporting of adverse events in pediatric patients receiving the COVID-19 vaccine, as well as the need for prompt diagnosis and management of potential vaccine-related complications. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu